| Date | Title | Description |
| 03.11.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | In the labyrinth of Alzheimer’s disease, a new light flickers. Lecanemab, a monoclonal antibody, has emerged as a promising treatment, showing potential to slow cognitive decline in early-stage patients. Recent data presented at the Clinica... |
| 01.11.2024 | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Fri, Nov 01, 2024 00:30 CET Report this content
Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: ... |
| 31.10.2024 | The Rise of Leqembi: A New Dawn in Alzheimer’s Treatment | In the world of Alzheimer’s research, a beacon of hope shines brighter than ever. Leqembi, a drug developed through a partnership between BioArctic and Eisai, is making waves. The latest reports reveal that Leqembi generated JPY 10 billion ... |
| 31.10.2024 | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Thu, Oct 31, 2024 08:30 CET Report this content
Stockholm, Sweden October 31, 2024 – BioArctic AB’... |
| 31.10.2024 | Recurrent Energy Announces Successful Operation of 134 MW Solar Project | Autodesk, Inc., Biogen Inc., EMD Electronics and Wayfair Inc. are now purchasing renewable energy from the Texas project
HOUSTON and GUELPH, ON, Oct. 31, 2024 /PRNewswire/ -- Recurrent Energy, a subsidiary of Canadian Solar Inc. ("Cana... |
| 30.10.2024 | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference | -New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab -
- Utilization of blood biomarkers to predict brain amyloid accumulati... |
| 30.10.2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
Wed, Oct 30, 2024 11:45 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 30.10.2024 | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
Wed, Oct 30, 2024 08:30 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Na... |
| 29.10.2024 | Massachusetts: The Beacon of Sustainable Biotech Innovation | Massachusetts is a powerhouse in biotechnology. It’s a state where innovation blooms like spring flowers. The rich soil of education, research, and collaboration nurtures groundbreaking advancements. This article explores how Massachusetts ... |
| 29.10.2024 | Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases | The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.
Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer... |
| 29.10.2024 | Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer | CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya... |
| 28.10.2024 | Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 | CAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Michael McDonnell, Biogen’s Executive Vice President and Chief Financial Officer, plans to retire from the company on February 28, 2025. Upo... |
| 27.10.2024 | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 | The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab
Felzartamab, an investigational anti-CD38 monoclonal antibody, is a ... |
| 27.10.2024 | The Role of Massachusetts in Promoting Sustainable Biotech Solutions | Share
Tweet
Share
Share
Email
Massachusetts stands at the forefront of biotechnology innovation, particularly in sustainable solutions. With a rich history in education and research, this state has nurtured an ecosystem that fosters groundb... |
| 26.10.2024 | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 | The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab
Felzartamab, an investigational anti-CD38 monoclonal antibody, is a ... |
| 24.10.2024 | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
Thu, Oct 24, 2024 08:00 CET Report this content
Stockholm, October 24, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented wit... |
| 22.10.2024 | Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 | Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathy
Additional oral presentation to examine the impact of felzartamab on key disease-relevant biomarkers
Felzartamab, an inves... |
| 17.10.2024 | BioArctic and Eisai: Navigating the Waters of Alzheimer’s Treatment | In the world of biopharma, few stories resonate as powerfully as the quest to combat Alzheimer’s disease. BioArctic AB, a Swedish company, stands at the forefront of this battle. Their flagship product, Leqembi® (lecanemab), has emerged as ... |
| 17.10.2024 | Eisai will request reconsideration of initial decision for lecanemab in Australia | Eisai will request reconsideration of initial decision for lecanemab in Australia
Thu, Oct 17, 2024 01:30 CET Report this content
Stockholm, Sweden October 17, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced to... |
| 08.10.2024 | New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA | Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to nusinersen Investigational regimen also shows ... |
| 07.10.2024 | Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases, Upcoming Webinar Hosted by Xtalks | www.labcorp.com
In this free webinar, learn about the rapidly evolving landscape of Alzheimer's disease therapy development and treatment. Attendees will gain insights into the key considerations for various platforms and strategies to inco... |
| 02.10.2024 | UAE TAKES THE LEAD IN AI AS INTERNATIONAL MARKETS FACE TALENT RACE TO MEET GLOBAL DEMAND | The Future AI Economy will take centre stage at GITEX GLOBAL 2024, the world’s largest tech and startup event, taking place from 14-18 October in Dubai
Dubai, UAE: The global surge in Artificial Intelligence (AI) investments propelled by th... |
| 16.09.2024 | Autoliv Welcomes Adriana Karaboutis: A New Era in Automotive Safety Leadership | In a strategic move that signals a commitment to innovation and leadership, Autoliv, Inc. has appointed Adriana Karaboutis to its Board of Directors. This decision, effective September 13, 2024, expands the board from eleven to twelve membe... |
| 16.09.2024 | Autoliv Appoints Adriana Karaboutis to its Board of Directors | STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, announces that it has added a new independent member to its Board of Directors effective today.
On Septem... |
| 16.09.2024 | Autoliv Appoints Adriana Karaboutis to its Board of Directors | Autoliv Appoints Adriana Karaboutis to its Board of Directors
Mon, Sep 16, 2024 08:00 CET Report this content
(Stockholm, Sweden, September 16, 2024) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety sy... |
| 15.09.2024 | SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit | NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the "... |
| 12.09.2024 | Biogen Board Appoints Two New Independent Directors | CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir... |
| 04.09.2024 | Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA | Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimen
Higher dose nusinersen regimen... |
| 04.09.2024 | Clouds of Care Secures 5 Million Euros to Propel CNS Healthcare Innovation and appoints former CEO of Biogen, Michel Vounatsos, as chairman of the board of directors | GHENT, Belgium, Sept. 4, 2024 /PRNewswire/ -- Clouds of Care, a leading MedTech company dedicated to enabling better care for people with Central Nervous System (CNS) disorders, proudly announces the successful closure of its funding round.... |
| 03.09.2024 | Remedy Pharmaceuticals Announces Further Analyses from Phase 3 Study Reveals CIRARA Could Significantly Improve Independent Ambulation in Large Hemispheric Infarction Patients | NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Remedy Pharmaceuticals today announced promising new data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 22.08.2024 | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
Thu, Aug 22, 2024 11:05 CET Report this content
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today t... |
| 14.08.2024 | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates
Wed, Aug 14, 2024 01:00 CET Report this content
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 05.08.2024 | Фармпроизводитель из США Biogen подал иск к Минздраву России | Суть иска американской фирмой не разглашается. Возможно, речь идет о споре из-за нарушения патентного права, связанного с препаратом «Лантесенс», пишет «Ъ».
«Спинраза» один из самых дорогих препаратов в мире, применяется для терапии всех ти... |
| 01.08.2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024
Thu, Aug 01, 2024 12:45 CET Report this content
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today ... |
| 31.07.2024 | Lecanemab: A Beacon of Hope in the Fight Against Alzheimer’s Disease | In the battle against Alzheimer’s disease, a new warrior has emerged: lecanemab, marketed as LEQEMBI. Recent findings presented at the Alzheimer’s Association International Conference (AAIC) 2024 reveal that this dual-acting antibody is not... |
| 31.07.2024 | AI Helps Scots Scientists Predict Diseases 10 Years in Advance | Scottish scientists using AI to analyse medical data have been able to predict a person’s probability of developing conditions such as heart disease, type 2 diabetes, Alzheimer’s up to 10 years before a diagnosis.
The researchers have used ... |
| 30.07.2024 | The New Frontier in Biotech: Partnerships and Innovations Shaping the Future of Medicine | In the ever-evolving landscape of biotechnology, partnerships are the lifeblood of innovation. Two recent collaborations highlight this trend: GSK's partnership with Flagship Pioneering and Autobahn Therapeutics' successful funding round. B... |
| 30.07.2024 | Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease | The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brain
These tools have the potential to be used to stratify patients or monitor treatment response for a ... |
| 30.07.2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms.
When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alz... | - 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
- Clinical Data and Biomarkers Show Alzheimer's Disease Does Not Stop Progressing... |
| 29.07.2024 | Autobahn Therapeutics: $100 Million Raised To Develop Restorative Treatments For Depression and Other CNS Disorders | Autobahn Therapeutics (a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders) announced the closing of an oversubscribed $100 million Series C funding led by Newpath... |
| 27.07.2024 | Lecanemab's EU Setback: A Race Against Time for Alzheimer's Treatment | In a world where time is a precious commodity, the recent decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has sent ripples of disappointment through the Alzheimer’s community. On ... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 27.07.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | The Alzheimer’s Association International Conference (AAIC) 2024 is set to unveil groundbreaking data on lecanemab, a drug that could reshape the landscape of Alzheimer’s disease (AD) treatment. As the conference approaches, excitement is p... |
| 26.07.2024 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 26.07.2024 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 26.07.2024 | CHMP has adopted a negative opinion on lecanemab for the EU | CHMP has adopted a negative opinion on lecanemab for the EU
Fri, Jul 26, 2024 12:40 CET Report this content
Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) h... |
| 26.07.2024 | Eisai will seek re-examination of CHMP opinion för lecanemab | Eisai will seek re-examination of CHMP opinion för lecanemab
Fri, Jul 26, 2024 13:15 CET Report this content
Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will req... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 24.07.2024 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec | – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –
– Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevu... |
| 23.07.2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024
Tue, Jul 23, 2024 08:00 CET Report this content
Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will presen... |
| 22.07.2024 | Charlie Forcey Joins Sustainability Roundtable, Inc. as CTO to Help Organize Off-Site Clean Energy Buyers Worldwide | BOSTON, July 22, 2024 /PRNewswire/ -- Sustainability Roundtable, Inc. (SR Inc), which works to be the world's most respected strategic advisor in enterprise decarbonization, announced today the appointment of Charlie Forcey to its C-Suite a... |
| 22.07.2024 | EISAI TO PRESENT DUAL-ACTING LECANEMAB THREE YEAR EFFICACY AND SAFETY DATA AND DISCUSS LONG-TERM OUTCOMES OF CONTINUED TREATMENT AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2024 | Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline will be shared, including the importance of continued treatment of AD, which is a progressive neurodegenerative disease that begins before plaque deposition and continues... |
| 16.07.2024 | Walking the Talk of Patient-Centricity in Cell and Gene Therapy Trials | JEEVA PRS 3
Remarkable progress in the development of cell and gene therapies (CGTx) has ignited hope for millions of patients battling debilitating human diseases including Central Nervous System (CNS) and neuromuscular diseases. However, ... |
| 15.07.2024 | ADM taps new executive VP, CFO | CHICAGO — ADM has named Monish Patolawala as executive vice president and chief financial officer, effective Aug. 1, succeeding Ismael Roig, who has been interim CFO since January.
Patolawala will be responsible for overseeing global financ... |
| 12.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Israel | Leqembi approved for the treatment of Alzheimer’s disease in Israel
Fri, Jul 12, 2024 01:30 CET Report this content
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqem... |
| 11.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong
Thu, Jul 11, 2024 01:30 CET Report this content
Stockholm, Sweden, July 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that th... |
| 10.07.2024 | BOLDEN THERAPEUTICS TO PRESENT AT THE 4TH ANNUAL OLIGONUCLEOTIDES FOR CNS SUMMIT | PROVIDENCE, R.I., July 10, 2024 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation... |
| 03.07.2024 | FDA approves new Alzheimer's treatment, donanemab from Eli Lilly | The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early stages of t... |
| 02.07.2024 | Lilly's Alzheimer's drug gets FDA nod | figcaption>span]:font-sans" data-chromatic="ignore">
The Food and Drug Administration granted approval to Eli Lilly's Alzheimer's drug, which was found to slow progression of the disease by about a third, the company an... |
| 02.07.2024 | Biogen Completes Acquisition of Human Immunology Biosciences | CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for ... |
| 02.07.2024 | UPDATE: FDA approves Lilly drug that can modestly slow Alzheimer’s disease | - |
| 02.07.2024 | Biogen Completes Acquisition of Human Immunology Biosciences | CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for ... |
| 28.06.2024 | Leqembi[®] (lecanemab) launched in China | Leqembi[®] (lecanemab) launched in China
Fri, Jun 28, 2024 01:30 CET Report this content
Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in Ch... |
| 27.06.2024 | “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China | TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 26.06.2024 | McKinney Launches 15th Annual Food and Beverage Trends Report | Declares 2024 Consumer Macro Trend: "Vibe Whiplash"
NEW YORK, June 26, 2024 /PRNewswire/ -- Creative, media, and influencer agency McKinney has unveiled its 15th Annual Food and Beverage Trends Report, centered around the overarch... |
| 24.06.2024 | TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union | TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by Biogen
Cambridge, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted approval for... |
| 17.06.2024 | CARINGKIND RAISES $1.4 MILLION IN SUPPORT OF ALZHEIMER'S AND RELATED DEMENTIA CARE AT THE 28TH ANNUAL FORGET-ME-NOT GALA | NEW YORK, June 17, 2024 /PRNewswire/ -- CaringKind, the trusted partner in Alzheimer's and related dementia caregiving for over 45 years, hosted their 28th annual Forget-Me-Not Gala on Monday, June 3rd, 2024, at Cipriani 42nd Street. The no... |
| 12.06.2024 | Beghou Consulting expands end-to-end life sciences commercialization capabilities | Beghou Consulting supports the end-to-end life sciences brand lifecycle with a blend of deep domain knowledge, data science and advanced analytics expertise, and powerful technology.
Rohit Gupta, Abhigya Jain and Nilanshu Sinha become new P... |
| 10.06.2024 | Lilly's Alzheimer's drug faces delayed reckoning | figcaption>span]:font-sans" data-chromatic="ignore">
The outlook for the latest experimental drug shown to delay Alzheimer's disease will come into focus Monday, when Food and Drug Administration advisers review an appl... |
| 10.06.2024 | WWDC 2024 Highlights: iOS 18 Brings Enhanced Privacy Controls to iPhone | By Quincy Jon
Published Jun 10, 2024 9:26PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
The Food and Drug Administration's (FDA) advisory committee endorsed Monday (June 10) El... |
| 09.06.2024 | FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 04.06.2024 | Melissa Seymour to join Lilly as executive vice president of Global Quality | INDIANAPOLIS, June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective... |
| 03.06.2024 | Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi® (bevacizumab), a Biosimilar Referencing Avastin® | CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing Avzivi® to the reference product Avastin®
GUANGZHOU, China, June 3, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commerc... |
| 30.05.2024 | US, UK in focus as pharma companies eye $31 billion exports in FY25 | - |
| 29.05.2024 | Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Pha... | NEW YORK, May 29, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a pioneer in stroke drug development, announced that prespecified subgroup analyses from the Phase 3 CHARM clinical trial of CIRARA (IV glibenclamide) showed meaningful improvem... |
| 24.05.2024 | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
Fri, May 24, 2024 12:55 CET Report this content
Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry o... |
| 22.05.2024 | Biogen купит биотехкомпанию Human Immunology Biosciences на сумму до $1,8 млрд | В среду компания Biogen заявила, что согласилась купить частную компанию Human Immunology Biosciences, получив доступ к таргетной терапии для пациентов с тяжелыми иммунозависимыми заболеваниями.
Сделка включает аванс в размере $1,15 млрд и ... |
| 15.05.2024 | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
Wed, May 15, 2024 01:30 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasda... |
| 15.05.2024 | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025) | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)
Wed, May 15, 2024 05:45 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 14.05.2024 | Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track St... | TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbac... |
| 02.05.2024 | Biotech Buyers Beware: 3 Stocks to Avoid The biotech industry is flourishing due to groundbreaking developments in cell and gene therapies and the rapid adoption of new technologies. However, not all ... | - |
| 24.04.2024 | Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024 | Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Wed, Apr 24, 2024 12:45 CET Report this content
Stockholm, Sweden, April 24, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 24.04.2024 | Govt expands committee for drugs, medical devices pricing reforms | - |
| 15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - |
| 09.04.2024 | Merck Life Science gets new MD | Merck has appointed Dhananjay Singh as Managing Director of Merck Life Science, in India. He takes over from Sreenath NS, who retires after 36 years with Merck in the country.
Also read:Merck, Novo Nordisk, Gilead, Biogen and more: Here are... |
| 01.04.2024 | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed
Mon, Apr 01, 2024 01:40 CET Report this content
Stockholm, Sweden, April 1, 2024 – BioArctic AB’... |
| 22.03.2024 | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
Fri, Mar 22, 2024 12:30 CET Report this content
Stockholm, Sweden March 22, 2024 – BioArctic AB:... |
| 19.03.2024 | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease
Tue, Mar 19, 2024 08:00 CET Report this content
Stockholm, Sweden, March 19, 2024 – B... |
| 13.03.2024 | После вмешательства генпрокурора РФ 68 южноуральцев обеспечены лекарствами | - |
| 13.03.2024 | AI Impact Tour arrives in Boston on March 27: A focus on data integrity in generative AI | Join leaders in Boston on March 27 for an exclusive night of networking, insights, and conversation. Request an invite here.
On March 27, we’ll host the next installment of our AI Impact Tour in Boston, focusing on the practical application... |
| 12.03.2024 | How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay? | Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements.
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral ... |
| 11.03.2024 | New data on lecanemab presented at the 2024 AD/PD™ congress | New data on lecanemab presented at the 2024 AD/PD™ congress
Mon, Mar 11, 2024 08:00 CET Report this content
Stockholm, March 11, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai presented new data on lecanemab (br... |
| 08.03.2024 | FDA delays action on Lilly's Alzheimer's drug | The Food and Drug Administration is asking outside advisors to review the safety and efficacy of an experimental Alzheimer's drug from Eli Lilly that was expected to be approved in the first quarter of this year.
Why it matters: Donanemab w... |
